RxDoctor Payments Data

Kent Wong, MD

Cardiovascular Disease · Modesto, CANPI 1386628212

Payments from drug & device makers

$23,868in general payments, 2019–2025

Across 380 payments — averaging $62.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$9K
  • Medtronic$7K
  • Abbott$5K
  • Edwards Lifesciences$783
  • Abiomed$477
  • Shockwave Medical, Inc$269
  • plus $935 from 16 others

What the payments were for

  • Travel & lodging$5,49423%
  • Food & beverage$8,92437%
  • Other$9,45040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,868 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$641,794
Medicare patients
1,460
Services billed
6,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban914$920,241
BrilintaTicagrelor290$189,730
EntrestoSacubitril/Valsartan59$87,440
XareltoRivaroxaban86$81,762
JardianceEmpagliflozin48$48,312
FarxigaDapagliflozin Propanediol19$25,495
Repatha SureclickEvolocumab19$19,037
ClopidogrelClopidogrel Bisulfate1,147$16,315
Dofetilide47$9,416
Diltiazem 12hr ErDiltiazem Hcl33$9,080
Propafenone Hcl179$9,051
Dabigatran EtexilateDabigatran Etexilate Mesylate23$8,323
Flecainide Acetate143$7,613
Carvedilol708$6,640
Atorvastatin Calcium554$6,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$920,241914 claims
NovartisEntresto$19$87,44059 claims
Johnson & JohnsonXarelto$159$81,76286 claims
Boehringer IngelheimJardiance$18$48,31248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →